Former FDA officials, including key figures like Richard Pazdur and Sheryl Lard-Whiteford, have shared their experiences and reasons for leaving during the second Trump administration. This provides critical insights into the agency's challenges and could influence how tech professionals approach collaborations with regulatory bodies in health tech. Watch for potential reforms or changes in FDA leadership that may affect drug approval processes.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
6
Ali NematiWritten by Ali
